In this study a new Hepatitis B virus (HBV) DNA vaccine capable of eliciting both humoral and cell-mediated immune responses was developed in an effort to combat the 600,000 annual new cases of HBV, which are added to the 370 million people already suffering from chronic infection. HBV infects human liver cells, leading to cirrhosis of the liver and eventually hepatocellular carcinoma.
The vaccine was designed to include plasmids expressing sequences from the major surface protein, major S as well as plasmids expressing a synthetic consensus HBV core antigen. When the plasmids were combined to form a multivalent cocktail vaccine, they were capable of stimulating strong immune responses in monkeys and mice.
|DNA vaccine cocktail
genotype A and C
HBV surface and consensus core antigens generates robust cytotoxic and
responses in mice and
Obeng-Adjei, N et al. (2013) Cancer Gene Therapy. 20: 652–662.
- The authors of this publication used GenScript's custom peptide library services.
- Click here to search for other publications that cite GenScript's peptide services.
- For an instant peptide synthesis quote try our online ordering system.